title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220930T210000,https://www.globenewswire.com/news-release/2022/09/30/2526351/0/en/Pyxis-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,IREHF,0.108466,Neutral,0.004586
"Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update",20220815T110000,https://www.globenewswire.com/news-release/2022/08/15/2498065/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2022-and-Provides-Pipeline-Update.html,IREHF,0.024597,Neutral,0.003808
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220712T104500,https://www.globenewswire.com/news-release/2022/07/12/2477876/0/en/Pyxis-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,IREHF,0.117486,Neutral,0.008539
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference,20220628T103500,https://www.globenewswire.com/news-release/2022/06/28/2470170/0/en/Pyxis-Oncology-to-Present-at-H-C-Wainwright-Preclinical-Cancer-Drug-Discovery-Conference.html,IREHF,0.150404,Neutral,0.139928
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference,20220628T103500,https://www.benzinga.com/pressreleases/22/06/g27877377/pyxis-oncology-to-present-at-h-c-wainwright-preclinical-cancer-drug-discovery-conference,IREHF,0.126985,Neutral,0.148558
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences,20220519T103500,https://www.globenewswire.com/news-release/2022/05/19/2446722/0/en/Pyxis-Oncology-Announces-Presentations-at-Upcoming-Investor-Conferences.html,IREHF,0.163243,Neutral,0.148916
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences,20220519T103500,https://www.benzinga.com/pressreleases/22/05/g27296022/pyxis-oncology-announces-presentations-at-upcoming-investor-conferences,IREHF,0.135959,Neutral,0.112749
"Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update",20220513T120300,https://www.globenewswire.com/news-release/2022/05/13/2442993/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Quarter-Ended-March-31-2022-and-Provides-Business-Update.html,IREHF,0.043826,Neutral,0.14774
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference,20220427T103500,https://www.globenewswire.com/news-release/2022/04/27/2429991/0/en/Pyxis-Oncology-to-Participate-in-Fireside-Chat-at-BofA-Securities-2022-Healthcare-Conference.html,IREHF,0.160099,Neutral,0.148916
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference,20220427T103500,https://www.benzinga.com/pressreleases/22/04/g26833162/pyxis-oncology-to-participate-in-fireside-chat-at-bofa-securities-2022-healthcare-conference,IREHF,0.135347,Neutral,0.112749
Pyxis Oncology Announces Leadership Changes,20220413T103500,https://www.globenewswire.com/news-release/2022/04/13/2421745/0/en/Pyxis-Oncology-Announces-Leadership-Changes.html,IREHF,0.03368,Somewhat-Bullish,0.158098
"Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T  ( PYX-106 )  Presented by Biosion, Inc. at the 2022 American Association for Cancer Research  ( AACR )  Annual Meeting",20220408T170500,https://www.benzinga.com/pressreleases/22/04/g26549673/pyxis-oncology-announces-preclinical-data-on-anti-siglec-15-bsi-060t-pyx-106-presented-by-biosion-,IREHF,0.049547,Neutral,0.126674
"Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T  ( PYX-106 )  Presented by Biosion, Inc. at the 2022 American Association for Cancer Research  ( AACR )  Annual Meeting",20220408T170500,https://www.globenewswire.com/news-release/2022/04/08/2419469/0/en/Pyxis-Oncology-Announces-Preclinical-Data-on-Anti-Siglec-15-BSI-060T-PYX-106-Presented-by-Biosion-Inc-at-the-2022-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,IREHF,0.037253,Somewhat-Bullish,0.158098
Pyxis Oncology Provides Corporate and Financial Update,20220329T103500,https://www.globenewswire.com/news-release/2022/03/29/2411693/0/en/Pyxis-Oncology-Provides-Corporate-and-Financial-Update.html,IREHF,0.033111,Neutral,0.14774
"Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022",20220322T103500,https://www.globenewswire.com/news-release/2022/03/22/2407381/0/en/Pyxis-Oncology-to-Host-Corporate-Update-Conference-Call-and-Webcast-on-March-29-2022.html,IREHF,0.158207,Somewhat-Bullish,0.158098
"Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022",20220322T103500,https://www.benzinga.com/pressreleases/22/03/g26234857/pyxis-oncology-to-host-corporate-update-conference-call-and-webcast-on-march-29-2022,IREHF,0.096827,Neutral,0.126674
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.benzinga.com/pressreleases/22/04/g26646216/cytomx-therapeutics-announces-retirement-of-john-a-scarlett-m-d-from-board-of-directors,IREHF,0.065595,Bullish,0.690191
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.globenewswire.com/news-release/2022/04/14/2423090/37704/en/CytomX-Therapeutics-Announces-Retirement-of-John-A-Scarlett-M-D-from-Board-of-Directors.html,IREHF,0.03564,Bullish,0.610195
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer,20230125T130100,https://www.globenewswire.com/news-release/2023/01/25/2595153/0/en/Pliant-Therapeutics-Announces-Appointment-of-Lily-Cheung-as-Chief-Human-Resources-Officer.html,IREHF,0.051003,Neutral,0.024932
